A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Alpelisib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.
- 26 Sep 2017 Planned initiation date changed from 1 May 2017 to 1 Sep 2017.
- 05 May 2017 New trial record